Join our daily newsletter At The Bell to receive exclusive market insights
- Clinical stage cell therapy company Chimeric Therapeutics (CHM) has completed the planned dosing of the first patient cohort of its phase one trial
- The phase one dose-escalation study evaluates the safety and maximum tolerated dose of Chimeric’s Chlorotoxin Car T in patients with recurrent or progressive gliblastoma (GBM)
- The study will enrol 18 to 36 patients with MMP2+ recurrent or progressive GBM across four dose levels
- The study will begin to recruit patients for the next dose level after the final patients from this cohort successfully complete the dosing period
- Shares are down 3.08 per cent, trading at 31.5 cents
Clinical stage cell therapy company Chimeric Therapeutics (CHM) has completed the planned dosing of the first patient cohort of its phase one trial.
The phase one dose escalation study evaluates the safety and maximum tolerated dose of Chimeric’s Chlorotoxin Car T in patients with recurrent or progressive gliblastoma (GBM).
Chlorotoxin CAR T is the first therapy of its kind that has the potential to address the high unmet medical need of patients with glioblastoma.
The study aims to enrol 18 to 36 patients with MMP2+ recurrent or progressive GBM across four dose levels, with the objective to evaluate the safety and efficacy of Chlorotoxin CAR T and establish what the recommended dosing should be for a phase two trial.
Patients in this dose cohort were given the treatment via single-site administration.
As this is a first in human phase one cell therapy trial, the four patients dosed within the first cohort received staggered treatment. Staggard treatment requires a follow-up interval between the administration of the product to one patient and administration of the product to the next patient, allowing for the sequential treatment of patients with an interval long enough to monitor any adverse events between dosings.
The study will begin to recruit patients for the next dose level after the final patients from this cohort successfully completes the dosing period.
Chimeric says it believes cellular therapies have the potential to cure cancer by combining its expertise in the development and commercialisation of cell therapies with the world’s most innovative scientists.
Shares are down 3.08 per cent, trading at 31.5 cents at 11:20 am AEDT.
